Antibody responses to common viruses according to COVID-19 severity and postacute sequelae of COVID-19

dc.contributor.authorKarachaliou, Marianna
dc.contributor.authorRanzani, Otavio
dc.contributor.authorEspinosa, Ana
dc.contributor.authorIraola Guzmán, Susana
dc.contributor.authorCastaño Vinyals, Gemma
dc.contributor.authorVidal, Marta
dc.contributor.authorJiménez, Alfons
dc.contributor.authorBañuls, Marc
dc.contributor.authorAlonso Nogués, Eva
dc.contributor.authorAguilar, Ruth
dc.contributor.authorGarcía Aymerich, Judith
dc.contributor.authorCid Ibeas, Rafael de
dc.contributor.authorDobaño, Carlota
dc.contributor.authorMoncunill, Gemma
dc.contributor.authorKogevinas, Manolis
dc.date.accessioned2024-11-13T07:08:19Z
dc.date.available2024-11-13T07:08:19Z
dc.date.issued2024
dc.description.abstractLimited research suggests that certain viruses reactivate in severe-acute-respiratory-syndrome-coronavirus 2 infection, contributing to the development of postacute sequelae of COVID-19 (PASC). We examined 1083 infected individuals from a population-based cohort, and assessed differences in plasma immunoglobulin (Ig)G and immunoglobulin A levels against Epstein-Barr virus (EBV), cytomegalovirus, varicella zoster virus (VZV), BK polyomavirus, KI polyomavirus, WU polyomavirus (WUPyV), respiratory syncytial virus, and Adv-36 according to the severity of previous COVID-19 and PASC history. Individuals who had experienced severe COVID-19 had higher antibody responses to latent viruses. Ever PASC, active persistent PASC, and PASC with neuropsychiatric symptoms were associated with higher immnoglobulin G to EBV early antigen-diffuse, VZV, and WUPyV even among individuals without previous severe COVID-19.
dc.format.mimetypeapplication/pdf
dc.identifier.citationKarachaliou M, Ranzani O, Espinosa A, Iraola-Guzmán S, Castaño-Vinyals G, Vidal M, et al. Antibody responses to common viruses according to COVID-19 severity and postacute sequelae of COVID-19. J Med Virol. 2024 Sep;96(9):e29862. DOI: 10.1002/jmv.29862
dc.identifier.doihttp://dx.doi.org/10.1002/jmv.29862
dc.identifier.issn0146-6615
dc.identifier.urihttp://hdl.handle.net/10230/68507
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofJ Med Virol. 2024 Sep;96(9):e29862
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/HE/101046314
dc.rights© 2024 The Author(s). Journal of Medical Virology published by Wiley Periodicals LLC. This is an open access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.keywordCOVID‐19
dc.subject.keywordHerpesviruses
dc.subject.keywordLong COVID
dc.subject.keywordPolyomaviruses
dc.subject.keywordPostacute sequelae of COVID‐19
dc.titleAntibody responses to common viruses according to COVID-19 severity and postacute sequelae of COVID-19
dc.typeinfo:eu-repo/semantics/article
dc.type.versioninfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
Karachaliou_jmv_anti.pdf
Mida:
634.94 KB
Format:
Adobe Portable Document Format

Llicència

Drets